1887
Research Open Access
Like 0

Abstract

Background

The progression and geographical distribution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United Kingdom (UK) and elsewhere is unknown because typically only symptomatic individuals are diagnosed. We performed a serological study of blood donors in Scotland in the spring of 2020 to detect neutralising antibodies to SARS-CoV-2 as a marker of past infection and epidemic progression.

Aim

Our objective was to determine if sera from blood bank donors can be used to track the emergence and progression of the SARS-CoV-2 epidemic.

Methods

A pseudotyped SARS-CoV-2 virus microneutralisation assay was used to detect neutralising antibodies to SARS-CoV-2. The study comprised samples from 3,500 blood donors collected in Scotland between 17 March and 18 May 2020. Controls were collected from 100 donors in Scotland during 2019.

Results

All samples collected on 17 March 2020 (n = 500) were negative in the pseudotyped SARS-CoV-2 virus microneutralisation assay. Neutralising antibodies were detected in six of 500 donors from 23 to 26 March. The number of samples containing neutralising antibodies did not significantly rise after 5–6 April until the end of the study on 18 May. We found that infections were concentrated in certain postcodes, indicating that outbreaks of infection were extremely localised. In contrast, other areas remained comparatively untouched by the epidemic.

Conclusion

Although blood donors are not representative of the overall population, we demonstrated that serosurveys of blood banks can serve as a useful tool for tracking the emergence and progression of an epidemic such as the SARS-CoV-2 outbreak.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2020.25.42.2000685
2020-10-22
2024-11-21
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2020.25.42.2000685
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/25/42/eurosurv-25-42-6.html?itemId=/content/10.2807/1560-7917.ES.2020.25.42.2000685&mimeType=html&fmt=ahah

References

  1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199-207.  https://doi.org/10.1056/NEJMoa2001316  PMID: 31995857 
  2. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-9.  https://doi.org/10.1038/s41586-020-2008-3  PMID: 32015508 
  3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.  https://doi.org/10.1016/S0140-6736(20)30566-3  PMID: 32171076 
  4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.  https://doi.org/10.1016/S0140-6736(20)30183-5  PMID: 31986264 
  5. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465-9.  https://doi.org/10.1038/s41586-020-2196-x  PMID: 32235945 
  6. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25(10).  https://doi.org/10.2807/1560-7917.ES.2020.25.10.2000180  PMID: 32183930 
  7. Byambasuren O, Cardona M, Bell K, Clark J, McLaws M-L, Glasziou P. Estimating the extent of true asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. medRxiv. 2020;2020.05.10.20097543; https://doi.org/ https://doi.org/10.1101/2020.05.10.20097543 
  8. Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol. 2020;101(8):791-7.  https://doi.org/10.1099/jgv.0.001439  PMID: 32430094 
  9. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200-4.  https://doi.org/10.1038/s41591-020-0965-6  PMID: 32555424 
  10. Liu A, Li Y, Peng J, Huang Y, Xu D. Antibody responses against SARS-CoV-2 in COVID-19 patients. J Med Virol. 2020;jmv.26241.  https://doi.org/10.1002/jmv.26241  PMID: 32603501 
  11. Gallais F, Velay A, Wendling M-J, Nazon C, Partisani M, Sibilia J, et al. Intrafamilial exposure to SARS-CoV-2 induces cellular immune response without seroconversion. medRxiv. 2020;2020.06.21.20132449 http://dx.doi.org/ https://doi.org/10.1101/2020.06.21.20132449 
  12. Seow J, Graham C, Merrick B, Acors S, Steel K, Hemmings O, et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. medRxiv. 2020;2020.07.09.20148429 http://dx.doi.org/10.1101/2020.07.09.20148429
  13. Riley S, Ainslie K, Eales O, Jeffrey B, Walters C, Atchison C, et al. Community prevalence of SARS-CoV-2 virus in England during May 2020: REACT study. medRxiv. 2020;2020.07.10.20150524; http://dx.doi.org/10.1101/2020.07.10.20150524
  14. Public Health England. UK government coronavirus data. London: UK Government; 20 May 2020. Available from: https://coronavirus.data.gov.uk
  15. Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9(1):680-6.  https://doi.org/10.1080/22221751.2020.1743767  PMID: 32207377 
  16. Adams ER, Ainsworth M, Anand R, Andersson MI, Auckland K, Baillie JK, et al. Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. Wellcome Open Res. 2020;5:139.  https://doi.org/10.12688/wellcomeopenres.15927.1 
  17. R Development Core Team R. R. A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2011. p. 409. Available from: http://www.R-project.org/
  18. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313-9.  https://doi.org/10.1016/S0140-6736(20)31304-0  PMID: 32534626 
  19. Plummer M. JAGS: A program for analysis of Bayesian models using Gibbs sampling. Proceedings of the 3rd International Workshop on Distributed Statistical Computing; Vienna, Austria; 20-22 Mar 2003. p. 125. Available from: https://www.r-project.org/conferences/DSC-2003/Proceedings/Plummer.pdf
  20. Harvala H, Robb M, Watkins N, Ijaz S, Dicks S, Patel M, et al. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. medRxiv. 2020;2020.05.20.20091694. http://dx.doi.org/10.1101/2020.05.20.20091694
  21. Gaunt ER, Hardie A, Claas ECJ, Simmonds P, Templeton KE. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol. 2010;48(8):2940-7.  https://doi.org/10.1128/JCM.00636-10  PMID: 20554810 
  22. Scottish Government. Coronavirus: first case is confirmed in Scotland. Edinburgh: Scottish Government; 1 March 2020. Available from: https://www.gov.scot/news/coronavirus-covid-19
/content/10.2807/1560-7917.ES.2020.25.42.2000685
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error